Kadmon Holdings, Inc.
Please note: The information displayed on this page might be outdated.
Kadmon Holdings, Inc.:
Aug 30 PDUFA data for belumosudil (cGVHD) following positive primary analysis results (May 2020); observed ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Initiating 12-15 pt open-label Ph 2 in patients w diffuse cutaneous systemic sclerosis in Q1 2021. First 3-pt dose cohort successfully completed in ongoing dose-escalation Ph 1 (anti-PD-L1/IL-15 fusion protein) in patients w metastatic or locally advanced solid tumors; enrollment ongoing in next dose level. Continuing IND-enabling activities of KD045, Kadmon's next-gen ROCK inhibitor for treatment of fibrotic diseases.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase III
Disease Space
Autoimmune, Fibrosis, Immunotherapy, Oncology
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
450 East 29th Street
New York, NY 10016
United States
New York, NY 10016
United States
More info:
My account:
Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls
- Harlan W. Waksal, MD, President & Chief Executive Officer
Lead Programs
KD025
| Indication | Phase |
|---|---|
| Chronic Graft-Versus-Host Disease | 2 |
| Systemic Sclerosis | 2 |
| Idiopathic Pulmonary Fibrosis | 2 |
KD034
| Indication | Phase |
|---|---|
| Wilson’s Disease | 3 |
Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0.00 | 0 | 0.00 | 13F | 3/31/21 |
Top 10 Holders of Kadmon Holdings, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 9.14 | 15,711,334 | 64.57 | 13F | 3/31/21 |
| State Street Corp. | 7.53 | 12,930,224 | 53.14 | 13F | 3/31/21 |
| Point72 Asset Management LP (Old) | 6.86 | 11,785,115 | 48.44 | 13F | 3/31/21 |
| SSgA Funds Management, Inc. | 5.72 | 9,815,097 | 40.34 | Stakes | 12/31/20 |
| Avidity Partners Management LP | 5.55 | 9,544,200 | 39.23 | 13F | 3/31/21 |
| Point72 Asset Management LP | 5.28 | 9,049,800 | 37.19 | Stakes | 1/13/21 |
| The Vanguard Group, Inc. | 5.25 | 9,002,368 | 37.00 | Stakes | 12/31/20 |
| Vanguard Group, Inc. (Subfiler) | 5.04 | 8,658,772 | 35.59 | 13F | 3/31/21 |
| BlackRock Fund Advisors | 4.70 | 8,071,604 | 33.17 | 13F | 3/31/21 |
| Third Point LLC | 4.42 | 7,601,115 | 31.24 | 13F | 3/31/21 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.